Format

Send to

Choose Destination
PLoS One. 2016 Jun 6;11(6):e0157024. doi: 10.1371/journal.pone.0157024. eCollection 2016.

A Novel Truncated Form of Serum Amyloid A in Kawasaki Disease.

Author information

1
Department of Pediatrics, Stanford University, Stanford, California, United States of America.
2
Department of Surgery, Stanford University, Stanford, California, United States of America.
3
Department of Pediatrics, University of California San Diego, La Jolla, California, United States of America, and Rady Children's Hospital-San Diego, San Diego, California, United States of America.

Abstract

BACKGROUND:

Kawasaki disease (KD) is an acute vasculitis in children that can cause coronary artery abnormalities. Its diagnosis is challenging, and many cytokines, chemokines, acute phase reactants, and growth factors have failed evaluation as specific biomarkers to distinguish KD from other febrile illnesses. We performed protein profiling, comparing plasma from children with KD with febrile control (FC) subjects to determine if there were specific proteins or peptides that could distinguish the two clinical states.

MATERIALS AND METHODS:

Plasma from three independent cohorts from the blood of 68 KD and 61 FC subjects was fractionated by anion exchange chromatography, followed by surface-enhanced laser desorption ionization (SELDI) mass spectrometry of the fractions. The mass spectra of KD and FC plasma samples were analyzed for peaks that were statistically significantly different.

RESULTS:

A mass spectrometry peak with a mass of 7,860 Da had high intensity in acute KD subjects compared to subacute KD (p = 0.0003) and FC (p = 7.9 x 10-10) subjects. We identified this peak as a novel truncated form of serum amyloid A with N-terminal at Lys-34 of the circulating form and validated its identity using a hybrid mass spectrum immunoassay technique. The truncated form of serum amyloid A was present in plasma of KD subjects when blood was collected in tubes containing protease inhibitors. This peak disappeared when the patients were examined after their symptoms resolved. Intensities of this peptide did not correlate with KD-associated laboratory values or with other mass spectrum peaks from the plasma of these KD subjects.

CONCLUSIONS:

Using SELDI mass spectrometry, we have discovered a novel truncated form of serum amyloid A that is elevated in the plasma of KD when compared with FC subjects. Future studies will evaluate its relevance as a diagnostic biomarker and its potential role in the pathophysiology of KD.

PMID:
27271757
PMCID:
PMC4894573
DOI:
10.1371/journal.pone.0157024
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center